Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be releasing its earnings data before the market opens on Wednesday, August 2nd. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.52 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its earnings results on Wednesday, May 10th. The company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.18). The firm had revenue of $3.66 billion during the quarter, compared to the consensus estimate of $3.60 billion. Teva Pharmaceutical Industries had a positive return on equity of 27.58% and a negative net margin of 10.73%. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Teva Pharmaceutical Industries Stock Down 2.8 %
Shares of NYSE TEVA opened at $8.40 on Wednesday. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 2.28. Teva Pharmaceutical Industries has a 52-week low of $7.09 and a 52-week high of $11.44. The firm’s fifty day moving average is $7.70 and its two-hundred day moving average is $8.88.
Analyst Ratings Changes
A number of research firms have issued reports on TEVA. Morgan Stanley began coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, May 25th. They issued an “equal weight” rating and a $10.00 target price on the stock. StockNews.com assumed coverage on Teva Pharmaceutical Industries in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. Evercore ISI upgraded shares of Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a report on Thursday, May 18th. Finally, UBS Group raised shares of Teva Pharmaceutical Industries from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $7.00 to $8.00 in a report on Thursday, July 6th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.44.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Large investors have recently modified their holdings of the business. BlackRock Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 3.7% in the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after buying an additional 1,494,814 shares in the last quarter. State Street Corp lifted its position in Teva Pharmaceutical Industries by 29.4% during the 1st quarter. State Street Corp now owns 19,564,828 shares of the company’s stock worth $172,988,000 after buying an additional 4,441,883 shares in the last quarter. Exor Capital LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 30.3% during the 4th quarter. Exor Capital LLP now owns 15,008,389 shares of the company’s stock worth $93,903,000 after acquiring an additional 3,486,202 shares during the period. Legal & General Group Plc increased its position in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Legal & General Group Plc now owns 9,683,798 shares of the company’s stock valued at $88,316,000 after acquiring an additional 1,534,941 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 3.2% in the first quarter. Geode Capital Management LLC now owns 6,752,562 shares of the company’s stock valued at $59,559,000 after buying an additional 207,161 shares in the last quarter. 49.69% of the stock is owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Teva Pharmaceutical Industries wasn’t on the list.
While Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.
